|Articles|June 21, 2021

June 2021
Volume 27
Issue 4

Weidner et al, Appendices

Author(s)Susan Weidner, MBA, MS, Michael Diaz, MD, Cass Schaedig

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

eAPPENDICES Weidner et al

Articles in this issue

almost 5 years ago

Article

Dollars and Sense

almost 5 years ago

Article

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

almost 5 years ago

Article

Observations Regarding the Average Sales Price Reimbursement Methodology

almost 5 years ago

Article

Real-World Evidence Is Key to Accelerating Oncology Approvals

almost 5 years ago

Article

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

almost 5 years ago

Article

almost 5 years ago

Article

A Social Worker Leads ACCC, and Her Timing Is Perfect

about 5 years ago

Article

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Dr Rahul Banerjee | Image Credit: Fred Hutch Cancer Center

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

ByBrooke McCormick,Rahul Banerjee, MD

June 13th 2026

Umberto Vitolo, MD | Image Credit: Candiolo Cancer Institute

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD

ByBrooke McCormick,Umberto Vitolo, MD

June 13th 2026

Nancy Lin, MD | Image Credit: Dana Farber Cancer Institute

Validation, Access, and Payer Consideration for AI Diagnostics in Breast Cancer: Nancy Lin, MD

ByElla Hohmann, MS,Nancy Lin, MD

June 12th 2026

Coral Omene, MD, PhD | Image Credit: Rutgers Cancer Institute

The Combination Changing the Neoadjuvant Calculus in Breast Cancer: Coral Omene, MD, PhD

ByElla Hohmann, MS,Coral Omene, MD, PhD

June 12th 2026

Colorectal screening | Image Credit: © Tom-stock.adobe.com

CRC Screening Program Narrowed Equity Gaps Over 9 Years

ByMaggie L. Shaw

June 12th 2026

Weidner et al, Appendices

Articles in this issue

Related Content

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD

Validation, Access, and Payer Consideration for AI Diagnostics in Breast Cancer: Nancy Lin, MD

The Combination Changing the Neoadjuvant Calculus in Breast Cancer: Coral Omene, MD, PhD

CRC Screening Program Narrowed Equity Gaps Over 9 Years

Trending on AJMC

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

5 FAQs: Ebola Outbreaks and the Challenge of Public Trust

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD